In a groundbreaking study, SNA-NPs conjugates, loaded with siRNA targeting Bcl2Like12 (Bcl2L12), a known p53 inhibitor overexpressed in GBM, were shown to successfully cross the BBB after systemic administration [431]. Here, TP53 is linked to glioblastoma.